Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Fellström, B. C. et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet
http://dx.doi.org/10.1016/S0140-6736(17)30550-0
(2017).
2. Spurio, F. F. et al. Low bioavailability and traditional systemic steroids in IBD: can the former take over the latter? J. Gastrointestin. Liver Dis. 22, 65–71 (2013).
3. Coppo, R. The gut–kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr. Nephrol.
http://dx.doi.org/10.1007/s00467-017-3652-1
(2017).
4. Kidney Disease Improving Global Outcomes. KDIGO clinical practice guidelines for glomerulonephritis. Immunoglobulin A nephropathy. Kidney Int. Suppl. 2, 209–220 (2012).
5. Pozzi, C. et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J. Am. Soc. Nephrol. 15, 157–163 (2004).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献